Hyperparathyroidism primary prevention

Revision as of 22:16, 29 July 2020 by WikiBot (talk | contribs) (Bot: Removing from Primary care)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Hyperparathyroidism Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hyperparathyroidism from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hyperparathyroidism primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hyperparathyroidism primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hyperparathyroidism primary prevention

CDC on Hyperparathyroidism primary prevention

Hyperparathyroidism primary prevention in the news

Blogs on Hyperparathyroidism primary prevention

Directions to Hospitals Treating Hyperparathyroidism

Risk calculators and risk factors for Hyperparathyroidism primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2]

Overview

Effective measures for the primary prevention of secondary hyperparathyroidism in chronic kidney disease include aggressive management of hyperphosphatemia in early stages of chronic kidney disease and prevention and treatment of vitamin D deficiency in stage 3 & 4 chronic kidney disease. There are no established measures for the primary prevention of primary hyperparathyroidism and tertiary hyperparathyroidism.

Primary Prevention

  • There are no established measures for the primary prevention of primary hyperparathyroidism and tertiary hyperparathyroidism.

References

  1. National Kidney Foundation (2003). "K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease". Am J Kidney Dis. 42 (4 Suppl 3): S1–201. PMID 14520607.

Template:WH Template:WS